After myeloablative treatment and allogeneic stem cell transplantation (ASCT), patients are kept isolated in the hospital to prevent infections during neutropenia. To date, 22 patients have been given the choice of being treated at home. Eleven could not be treated at home, and they served as controls. Most had haematological malignancies. The donors were 12 HLA-compatible unrelated, nine HLA-identical siblings and one twin. In the home care group, three developed bacteraemia, compared to nine in the controls (P Ͻ 0.01). Patients in the home care group had fewer days of total parenteral nutrition (median 3 vs 24, P Ͻ 0.001), required fewer erythrocyte transfusions (median 4 vs 8, P = 0.01), fewer days on i.v. antibiotics (median 6 vs 13 days), and on analgesics (median 0 vs 15) than the controls (P Ͻ 0.05). Days with fever, time to engraftment, days with G-CSF and acute GVHD were the same in the two groups. Seven of 11 patients treated at home were readmitted to the ward for a median of 3 (0-7) days, due to fever or lack of a caregiver at home. Days to discharge to the out-patient clinic were faster in the group treated at home (median 20 vs 35 days, P Ͻ 0.01). Patients who were treated at home enjoyed being active and taking a walk when they felt like it. This preliminary report suggests that home care after ASCT is not only safe, but superior to isolation in the hospital. Bone Marrow Transplantation (2000) 26, 1057-1060.
High doses of chemo-radiotherapy and allogeneic stem cell transplantation (ASCT) are increasingly used to treat haematological malignancies and other life-threatening disorders affecting the haematopoietic system. [1] [2] [3] Due to immunosuppression and neutropenia, complications with infections are common causes of morbidity and mortality. [4] [5] [6] To prevent infections, patients are kept in a protected environment such as laminar airflow rooms (LAF), reversed isolation, etc. 7 To improve quality of life and save money, home care is becoming popular. Its main applications have been palliative care in end-stage cancer patients and in geriatrics. 8, 9 In recent years, home care on an out-patient basis has been offered in some centres performing autologous stem cell transplantation. 9 In allograft recipients, Russell and colleagues 10 allowed patients to leave their rooms and the hospital freely. Patients living locally went home for a few hours, sometimes overnight. We used another approach in ASCT patients. To our knowledge, this has not been done before. The patients were given the opportunity of being treated at home. To start with, we wished to know whether it is safe to treat ASCT patients at home during the pancytopenic phase. This preliminary report concerns this prospective trial.
Materials and methods
Since March 1998, all patients living within one hour's driving distance from Huddinge Hospital undergoing ASCT and judged eligible by our medical team have been offered home care from the day of transplantation. We have also imposed various other requirements: (1) a caregiver, relative or friend willing to stay at home and help; (2) approval of the home by the Department of Infection Control. The Department's criteria must also be fulfilled: water-temperature Ͼ50°C, no flowers in pots (because the earth may contain Aspergillus), no animals, sheets must be changed three times a week and the home cleaned once a week.
Conditioning
Conditioning is given in the hospital, when the patient and caregiver are informed about the procedure. This consisted of cyclophosphamide (Cy) 60 mg/kg, for 2 days (total dose 120 mg/kg), combined with 10 Gy of total body irradiation (TBI), single fraction, with the lungs shielded to receive no more than 9 Gy or fractionated 3 Gy daily for 4 days. 11, 12 Busulfan (Bu) 4 mg/kg/day divided into four doses, was given for 4 days (total dose 16 mg/kg) and adjusted to Bu levels. 13, 14 It was combined with Cy 60 mg/kg for 2 days. Due to cardiac insufficiency in two patients, Cy was replaced by holoxane 60 mg/kg for 2 days. Two patients received fludarabine 30 mg/m 2 /day for 6 days, combined with Bu 4 mg/kg/day given for 2 days (total dose 8 mg/kg), combined with thymoglobulin (Sangstat, IMTIX, Lyons, France) 2 mg/kg/day for 4 days. 15 In patients given unrelated grafts, thymoglobulin 2 mg/kg/day was given for 2 days prior to ASCT. 11, 16 When the graft has been infused, the patient may go home. An experienced nurse from the ward visits the patient once or twice daily. She checks vital signs including temperature and blood pressure and examines the patient's mouth for mucositis, herpes lesions and fungi, as well as the skin for acute GVHD or other skin lesions. In the mornings, she takes blood samples from the central venous line (10-25 ml/day) and gives i.v. medications, erythrocyte transfusions when the patient has a Hb Ͻ80 g/l, and platelet transfusions when the platelet count falls below 30 × 10 9 /l, or if there are signs of haemorrhage. 11, 12 If the patient's fluid intake is less than 2 l, and the weight has decreased by more than 2 kg, parenteral nutrition is started. If the patient cannot feed himself at all, total parenteral nutrition (TPN) is given.
A physician calls the patient every day, after reviewing the test results. The patient is asked to check his temperature frequently. If it rises above 38.5°C, he is instructed to go to the hospital. Blood cultures and a chest X-ray are taken and i.v. antibiotics are started. After the check-up in the hospital for an infection and, if the patient feels well, he can go home even with fever, and i.v. antibiotics can be continued at home. Hospitalisation is advised if the patient feels too sick to stay at home or the caregiver cannot take care of the patient at home.
Patients in hospital were treated in conventional single rooms with reversed isolation. A relative or friend could stay with them in the room. 17 The patients were allowed to take a walk outside the hospital during weekends and after 6 p.m. on weekdays. 11, 16 Patients treated at home and in the hospital were advised to avoid contact with persons having contagious diseases. They were also told not to go near construction areas when out walking.
Blood cultures were taken the first time the patient had a temperature Ͼ38.5°C. Subsequent blood cultures were taken when patients had a high fever and chills. In the event of a continuous fever, blood cultures were taken two to three times weekly.
Patients
To date, 22 patients have been asked to participate. Eleven patients could not be treated at home because (1) there was no caregiver (n = 8), (2) a pet animal was in the home (two) and (3) one did not feel safe there. None was excluded because of their clinical condition. These patients served as the control group. Patient characteristics are given in Table 1 .
The disease was in first remission or chronic phase in 7/8 patients in the study group/controls, later remission 1/0 or relapse or accelerated phase in 3/3. Six of five patients were classified as high risk (beyond 1st remission or 1st chronic phase) and 5/6 as low risk.
Immunosuppression and donors
Cyclosporine (CYA) combined with methotrexate was given as prophylaxis against graft-versus-host disease (GVHD) (10/10). 11, 12, 16, 18, 19 One patient in the study group with a twin donor received no prophylaxis and one patient in the control group CYA and prednisolone. Donors were 
Statistics
Fisher's exact test was used to compare distributions of patients with septicaemia and the Mann-Whitney U test to compare days with fever, total parenteral nutrition (TPN), antibiotics, transfusions and other data. The median and range are given.
Results
Seven patients went home on the day of transplant or day +1. Three patients went home on day +3 and one on day +6 after ASCT since they had no caregiver at home. The first time patients developed a fever Ͼ38.5°C, they were taken to the hospital for blood cultures and a chest X-ray to ensure that they did not develop septic shock or acute respiratory distress syndrome at home. Seven of the 11 patients were readmitted to the ward for 2-7 days, median 4 days, because of fever (six) and no caregiver at home (one). A median of one blood culture (range 0-3) was taken from patients treated at home, compared to four (0-13) in the controls treated in hospital (P = 0.02). Those treated at home gained a median of +4 (+4 to −6) kg, as compared to a median of −1 (+10.6 to −5) kg in controls (NS). The patient who gained 10.6 kg in weight had ascites due to veno-occlusive disease of the liver. 20 Fewer patients treated at home had bacteraemia (3/9 patients), or required total parenteral nutrition (TPN) ( Table 2 ). They also needed fewer days on antibiotics or on analgesics and fewer erythrocyte transfusions. There were no significant differences between patients treated at home and those in the control group, regarding days with fever, platelet transfusions and treatment with G-CSF ( Table 2 ). Time to engraftment WBC Ͼ0.2 × 10 9 /l, neutrophils Ͼ0.5 × 10 9 and platelets Ͼ30 × 10 9 /l were the same in the two groups. The probability of developing acute GVHD grades II-IV was 0% in the study group and 18% in the controls. Days to discharge to the out-patient clinic were faster in the patients treated at home, compared to those in the hospital (Table  2 , P Ͻ 0.01). All patients treated at home survived until discharge to the out-patient clinic. One patient died 52 days after ASCT due to acute haemorrhagic pancreatitis. The other patients are alive and well between 4 and 17 months after transplantation. Three patients among the controls died from multiorgan failure (two) and GVHD (one). The others are alive and well 2-13 months after ASCT. All patients and their caregivers answered an anonymous questionnaire when they were discharged to the out-patient clinic. No patient treated at home regretted their decision. They were glad about having been able to stay with their family, take part in activities at home and walk when they felt like it.
Discussion
Our findings in this pilot study suggest that home care after ASCT is safe. Our main concern was the risk of adult respiratory distress syndrome or septic shock, which are fatal complications. Patients were therefore readmitted to the hospital if they developed a fever Ͼ38.5°C. In such cases, blood cultures and a chest X-ray were taken, antibiotics instituted and, if they were in good condition, they returned home. Although 55% were admitted because of fever, all of them were able to go home. Another concern was whether the risk of aspergillus pneumonia would increase in those who were not isolated, but no patient developed this complication. Indeed, aspergillus pneumonia was a rare Table 2 Results, median (range) Bone Marrow Transplantation complication in our ASCT patients. 21 However, there are too few patients in the study to draw any conclusions at present.
Some patients prefer home care to hospitalisation. It is only an option for some, since most of them come from other areas or abroad. It is probably cheaper, because fewer patients needed TPN, antibiotics and transfusions. The costs will be evaluated when more patients have been included in the trial. Moreover, the hospital beds seem to be used more effectively. An interesting finding was the lower incidence of bacteraemia. One possible explanation of this may be that there are fewer antibiotic-resistant bacteria and fungi in the home than in hospital. If the frequency of antibiotic-resistant bacteria should increase, for instance, the development of vancomycin-resistant enterococci, home care may come to be regarded as far superior to hospital care.
Our study confirms that by Russell et al, 10 who reported that strict isolation is not necessary. However, their patients were allowed to go home for a few hours or sometimes overnight, while ours stayed at home and were visited by our nurses. Our approach seems more convenient for the patients, but their approach may be cheaper, because it is time-consuming for nurses to make home visits.
Some authors have found reduced infection rates, especially regarding aspergillosis, in ASCT patients who are strictly isolated. 22, 23 A randomised trial also noted survival benefits in patients with severe aplastic anaemia treated in LAF rooms vs normal single rooms. 24 A study from the International Bone Marrow Transplant Registry showed higher survival rates in patients cared for with stricter isolation procedures in LAF rooms than those not treated in LAF rooms in the hospital. 25 However, in another prospective randomised trial, patients treated in LAF rooms had a significantly lower incidence of bacteraemia, but the same survival rates as those treated in conventional single rooms. 7 These studies only included hospitalised patients, but in hospitals many patients are treated for infections, which give rise to antibiotic-resistant bacteria. This does not occur at home.
Patients may need TPN less because they are more active and have a better appetite at home. They may also be encouraged to eat more food they like at home whenever they want. Just being away from the hospital may be an advantage. Home care patients are probably more motivated to eat.
Apart from its safety, home care seems to have several advantages, such as a lower frequency of bacteraemia, fewer days on TPN, fewer erythrocyte transfusions, fewer days on i.v. antibiotics and on analgesics than the controls. Since we only evaluated a few patients, a larger study is needed to definitely settle these issues.
To conclude, our preliminary findings suggest that home care during the pancytopenic phase after ASCT is safe, should be continued but more patients should be evaluated.
